A number of firms have modified their ratings and price targets on shares of Sorrento Therapeutics (NASDAQ: SRNE) recently:

  • 8/30/2017 – Sorrento Therapeutics was given a new $20.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/29/2017 – Sorrento Therapeutics was given a new $7.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/24/2017 – Sorrento Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
  • 8/22/2017 – Sorrento Therapeutics was given a new $7.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/10/2017 – Sorrento Therapeutics was given a new $7.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/4/2017 – Sorrento Therapeutics is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $7.00 price target on the stock.
  • 8/3/2017 – Sorrento Therapeutics is now covered by analysts at UBS AG. They set an “outperform” rating and a $7.00 price target on the stock.
  • 8/3/2017 – Sorrento Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $7.00 price target on the stock.

Sorrento Therapeutics Inc (SRNE) opened at 1.825 on Tuesday. The firm’s market capitalization is $125.87 million. Sorrento Therapeutics Inc has a 12-month low of $1.50 and a 12-month high of $8.35. The firm has a 50 day moving average of $1.81 and a 200 day moving average of $2.38.

In other Sorrento Therapeutics news, insider Henry Ji bought 29,001 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was purchased at an average cost of $1.81 per share, with a total value of $52,491.81. Following the transaction, the insider now directly owns 139,776 shares in the company, valued at approximately $252,994.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 5.00% of the company’s stock.

Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.

Receive News & Stock Ratings for Sorrento Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc and related stocks with our FREE daily email newsletter.